Adtralza
(Tralokinumab)Phase 3Monoclonal antibody
LEO PharmaTralokinumab is used to treat moderate to severe atopic dermatitis (eczema), a skin condition that causes itching, redness, and inflammation. It works by blocking a specific protein in the body that triggers the inflammatory response in the skin.[1] Adtralza is currently being investigated across 9 indications[3], with its most advanced program in Phase 3.[1]
Adtralza is one of 241 monoclonal antibody programs targeting Atopic Eczema. It is currently in Phase 3.
9
Indications
30
Total Trials
6
Active Trials
240
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Adtralza
LEO PharmaPhase 3
Gemzar
GGynecologic Oncology Group
Preclinical
Medrol
PfizerPreclinical
MS Contin
Merck & Co.Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
ABI-007
Bristol-Myers SquibbPreclinical
LDE225
NovartisPreclinical
Sulfonylureas
Eli LillyPreclinical
Thiazolidinediones
SanofiPreclinical
Alpha-Glucosidase Inhibitors
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atopic Dermatitis15 trials
Show 12 more trials
Asthma6 trials
Show 3 more trials
Alopecia Areata1 trial
6 more indications
Efficacy and Safety1 trial
Pregnancy1 trial
Idiopathic Pulmonary Fibrosis1 trial
Liver1 trial
Unspecified1 trial
Tralokinumab for Dupilumab Failures
Active, not recruiting·PPsoriasis Treatment Center of Central New Jersey·Phase 4·NCT06773455·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tralokinumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- IL-13 Inhibitor[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company